Erratum to Matrix metalloproteinases and peripheral arterial disease (Intern Emerg Med, DOI 10.1007/s11739-009-0283-y);Matrix metalloproteinases and peripheral arterial disease

Internal and Emergency Medicine

Volumn 5, Issue 1, 2010, Pages 13-25

  Busti, Chiara ^a   Falcinelli, Emanuela ^a   Momi, Stefania ^a   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Atherosclerosis; Biomarkers; Inflammation; Matrix metalloproteinases; Peripheral arterial disease; Platelets; Thrombosis

Indexed keywords

EID: 76049125185     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-009-0308-6     Document Type: Erratum

References (77)

1. Woessner JF (1993) Introduction to serial reviews: the extracellular matrix. FASEB J 7: 735-736.
2. Hobeika MJ (2007) Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg 45: 849-857.
3. Newby AC (2005) Dual role of matrix metalloproteinases (Matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85: 1-31.
4. Morgunova E, Tuuttila A, Bergmann U et al (1999) Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 284: 1667-1670.
5. van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87: 5578-5582.
6. Bassiouny HS, Song RH, Hong XF et al (1998) Flow regulation of 72 KD-collagenase IV (MMP-2) after experimental arterial injury. Circulation 98: 157-163.
7. Godin D, Ivan E, Johnson C et al (2000) Remodelling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 102: 2861-2866.
8. Chesler NC, Ku DN, Galis ZS (1999) Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol 277: H2002-H2009.
9. Reichenbach G, Momi S, Gresele P (2005) Nitric oxide and its antithrombotic action in the cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 5: 65-74.
10. Rajagopalan S, Meng XP, Ramasamy S et al (1996) Reactive oxygen species produced by macrophage-derived foam cells regulate activity of vascular matrix metalloproteinases in vitro. J Clin Invest 98: 2572-2579.
11. Frears ER, Zhang Z, Blake DR et al (1996) Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 381: 21-24.
12. Tayebjee MH, Lip GY, Blann AD et al (2005) Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases MMP-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases TIMP-1 and -2. Thromb Res 115: 205-210.
13. Ye S (2006) Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 69: 636-645.
14. Santos-Martínez MJ, Medina C, Jurasz P et al (2008) Role of metalloproteinases in platelet function. Thromb Res 121: 535-542.
15. Sawicki G, Salas E, Murat J et al (1997) Release of gelatinase A during platelet activation mediates aggregation. Nature 386: 616-619.
16. Falcinelli E, Guglielmini G, Torti M et al (2005) Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. J Thromb Haemost 3: 2526-2535.
17. Galt SW, Lindemann S, Allen L et al (2002) Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res 90: 1093-1099.
18. Pitchford SC, Momi S, Baglioni S et al (2008) Allergen induces the migration of platelets to lung tissue in allergic asthma. Am J Respir Crit Care Med 177: 604-612.
19. Santilli F, Basili S, Ferroni P et al (2007) CD40/CD40L system and vascular disease. Intern Emerg Med 2: 256-268.
20. Furman MI, Krueger LA, Linden MD et al (2004) Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 43: 2319-2325.
21. Emaitre V, O'Byrne TK, Borczuk AC et al (2001) ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 107: 1227-1234.
22. Ilence J, Lupu F, Collen D et al (2001) Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 21: 1440-1445.
23. Lijnen HR, van Hoef B, Lupu F et al (1998) Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 18: 1035-1045.
24. Galis ZS, Sukhova GK, Lark MW et al (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94: 2493-2503.
25. Brown DL, Hibbs MS, Kearney M et al (1997) Differential expression of 92-kDa gelatinase in primary atherosclerotic versus restenotic coronary lesions. Am J Cardiol 79: 878-882.
26. Jones CB, Sane DC, Herrington DM (2003) Matrix metalloproteinases: a review of their structure and role in acute coronary syndromes. Cardiovasc Res 59: 812-823.
27. Hojo Y, Ikeda U, Katsuki T et al (2002) Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 161: 185-192.
28. Galis ZS, Kranzhofer R, Fenton JW 2nd et al (1997) Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17: 483-489.
29. Gresele P, Falcinelli E, Momi S (2008) Potentiation and priming of platelet activation: a potential target of antiplatelet therapy. Trends Pharmacol Sci 29: 352-360.
30. Knox JB, Sukhova GK, Whittemore AD et al (1997) Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 95: 205-212.
31. Goodall S, Crowther M, Hemingway DM et al (2001) Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 104: 304-309.
32. Urbonavicius S, Urbonaviciene G, Honorè B et al (2008) Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture-a systematic review. Eur J Vasc Endovasc Surg 36: 273-280.
33. Sang QX (1998) Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8: 171-177.
34. Muhs BE, Plitas G, Delgado Y et al (2003) Temporal expression and activation of matrix metalloproteinases-2, -9, and membrane type 1-matrix metalloproteinase following acute hindlimb ischemia. J Surg Res 111: 8-15.
35. Lee S, Jilani SM, Nikolova GV et al (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169: 681-691.
36. Hangai M, Kitaya N, Xu J et al (2002) Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 161: 1429-1437.
37. Hessig B, Hattori K, Dias S et al (2002) Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9-mediated release of kit-ligand. Cell 109: 625-637.
38. Cai WJ, Koltai S, Kocsis E et al (2003) Remodeling of the adventitia during coronary arteriogenesis. Am J Physiol Heart Circ Physiol 284: H31-H40.
39. Jenkins GM, Crow MT, Bilato C et al (1998) Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation 97: 82-90.
40. Zang J, Nie L, Razavian M et al (2008) Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 118: 1953-1960.
41. Lijnen HR, Soloway P, Collen D (1999) Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. Circ Res 85: 1186-1191.
42. Guzman JR (2007) Clinical, cellular, and molecular aspects of arterial calcification. J Vasc Surg 45: A57-A63.
43. Lehto S, Rönnemaa T, Pyörälä K et al (1996) Risk factors predicting lower extremity amputations in patients with NIDDM. Diabetes Care 19: 607-612.
44. Basalyga DM, Simionescu DT, Xiong W et al (2004) Elastin degradation and calcification in an abdominal aorta injury model. Circulation 110: 3480-3487.
45. Qin X, Corriere MA, Matrisian LM et al (2006) Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol 26: 1510-1516.
46. Haugen S, Casserly IP, Regensteiner JG et al (2007) Risk assessment in the patient with established peripheral arterial disease. Vasc Med 12: 343-350.
47. Wilson AM, Kimura E, Harada RK et al (2007) B2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 116: 1396-1403.
48. Busti C, Migliacci R, Falcinelli E et al (2009) Plasma levels of beta(2)-microglobulin, a biomarker of peripheral arterial disease, are not affected by maximal leg exercise in patients with intermittent claudication. Atherosclerosis 203: 38-40.
49. Arpegrad J, Ostergren J, de Faire U et al (2008) Cystatine C-a marker of peripheral arterial disease? Atherosclerosis 199: 397-401.
50. Lucivero V, Prontera M, Mezzapesa DM et al (2007) Different roles of MMP-2 and-9 after human ischaemic stroke. Neurol Sci 28: 165-170.
51. Tayebjee MH, Lip GY, Tan KT et al (2005) Plasma matrix metalloproteinase-9 tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96: 339-345.
52. Blankenberg S, Rupprecht HJ, Poirier O et al (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579-1585.
53. Eldrup N, Gronholdt ML, Sillesen H et al (2006) Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 114: 1847-1854.
54. Signorelli SS, Malaponte G, Libra M et al (2005) Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med 10: 1-6.
55. Tayebjee MH, Tan KT, MacFadyen RJ et al (2005) Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J Intern Med 257: 110-116.
56. Falcinelli E, Giannini S, Boschetti E, Gresele P (2007) Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury. Brit J Haematol 138: 221-230.
57. Gresele P, Catalano M, Giammarresi C et al (1997) Platelet activation markers in patients with peripheral arterial disease-a prospective comparison of different platelet function tests. Thromb Haemost 78: 1434-1437.
58. Flex A, Gaetani E, Angelini F et al (2007) Pro-inflammatory genetic profiles in subjects with peripheral arterial occlusive disease and critical limb ischemia. J Intern Med 262: 124-130.
59. Adya R, Tan BK, Chen J et al (2008) Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabets Care 31: 758-760.
60. Worley JR, Hughes DA, Dozio N et al (2007) Low density lipoprotein from patients with Type 2 diabetes increases expression of monocyte matrix metalloproteinase and ADAM metalloproteinase genes. Cardiovasc Diabetol 22: 6-21.
61. Chen YH, Wu HL, Chen CK, Huang YH, Yang BC, Wu LW (2003) Angiostatin antagonizes the action of VEGF-A in human endothelial cells via two distinct pathways. Biochem Biophys Res Commun 310: 804-810.
62. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noel A (2002) The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 16: 1802-1804.
63. Chung AW, Hsiang YN, Matzke LA et al (2006) Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 99: 140-148.
64. Lauhio A, Sorsa T, Srinivas R et al (2008) Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. Ann Med 40: 312-320.
65. Gonçalves FM, Jacob-Ferreira AL, Gomes VA et al (2009) Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 403: 173-177.
66. Li L, Renier G (2008) The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells. Atherosclerosis [Epub ahead of print].
67. Forst T, Karagiannis E, Lübben G et al (2008) Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 197: 311-317.
68. Goldstein BJ, Weissman PN, Wooddell MJ et al (2006) Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Curr Med Res Opin 22: 1715-1723.
69. Lee CS, Kwon YW, Yang HM et al (2009) New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arterioscler Thromb Vasc Biol 29: 472-479.
70. Schieffer B, Bünte C, Witte J et al (2004) Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44: 362-368.
71. Yamamoto D, Takai S, Miyazaki M (2008) Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol 588: 277-279.
72. Bellosta S, Via D, Canavesi M et al (1998) HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18: 1671-1678.
73. Crisby M, Nordin-Fredriksson G, Shah PK et al (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques implications for plaque stabilization. Circulation 103: 926-933.
74. Xu Z, Zhao S, Zhou H et al (2004) Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clin Chem 50: 750-753.
75. Forrester JS, Libby P (2007) The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 99: 732-738.
76. Kenagy RD, Nikkari ST, Welgus HG et al (1994) Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Invest 93: 1987-1993.
77. Grzela T, Brawura-Biskupski-Samaha R et al (2008) Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm. Eur Vasc Endovasc Surg 35: 159-161.